ES2192394T3 - Profarmacos de inhibidores de la bomba de protones. - Google Patents
Profarmacos de inhibidores de la bomba de protones.Info
- Publication number
- ES2192394T3 ES2192394T3 ES99942057T ES99942057T ES2192394T3 ES 2192394 T3 ES2192394 T3 ES 2192394T3 ES 99942057 T ES99942057 T ES 99942057T ES 99942057 T ES99942057 T ES 99942057T ES 2192394 T3 ES2192394 T3 ES 2192394T3
- Authority
- ES
- Spain
- Prior art keywords
- carbons
- alkyl
- alkoxy
- substituted
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Pyridine Compounds (AREA)
- Reciprocating Pumps (AREA)
- Fertilizing (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Un compuesto de la fórmula Het1 - X - S(O)- Het2 en donde Het1 se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** X se selecciona a partir del grupo que consta de las estructuras mostradas por las fórmulas a continuación **(Fórmula)** y Het2 se selecciona a partir del grupo consistente en las estructuras mostradas por las fórmulas a continuación **(Fórmula)** en donde N en el resto bencimidazol representa que uno de los carbonos del anillo se puede intercambiar por un átomo de N no sustituido; **(Fórmula)** R1, R2 y R3 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con flúor, alquiltio de 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con flúor, alcoxialcoxi de 2 a 10 carbonos, amino, alquilamino y dialquilamino teniendo cada uno de los grupos alquilo en dichos grupos alquilamino y dialquilamino 1 a 10 carbonos, halógeno, fenilo, fenilo sustituido con alquilo, fenilo sustituido con alcoxi, fenilalcoxi, teniendo cada uno de los grupos alquilo en dicho fenilo sustituido con alquilo, fenilo sustituido con alcoxi y fenilalcoxi, 1 a 10 carbonos, piperidino, morfolino o dos de los grupos R1, R2y R3 forman conjuntamente un anillo de 5 o 6 miembros que tienen 0 o 1 heteroátomo seleccionado entre N, S y O; R4 y R5 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo sustituido con flúor de 1 a 10 carbonos, fenilalquilo, naftilalquilo y heteroarilalquilo, teniendo el alquilo en dichos grupos fenilalquilo, naftilalquilo y heteroarilalquilo 1 a 10 carbonos; R6, es hidrógeno, halógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con flúor, alcoxi que tiene 1 a 10 carbonos o alcoxi sustituido con flúor que tiene 1 a 10 carbonos; R6 a R9 se seleccionan independientemente entre hidrógeno, alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi de 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquil carbonilo, alcoxicarbonilo teniendo el grupo alquilo en dicho alquil carbonilo y alcoxicarbonilo 1 a 10 carbonos, oxazolilo, imidazolilo, tiazolilo, pirazolilo o cualquiera de los dos adyacentes a los grupos R6 a R9 puede formar un anillo que puede incluir opcionalmente un heteroátomo seleccionado entre N, O y S; R10 es hidrógeno, alquilo de 1 a 10 carbonos; R11 y R12 se seleccionan independientemente entre hidrógeno, halógeno, alquilo de 1 a 10 carbonos y alquilo de 1 a 10 carbonos sustituido con halógeno; R15 tiene la fórmula siguiente **(Fórmula)** en donde R17 es alquilo de 1 a 10 carbonos, alquilo de 1 a 10 carbonos sustituido con halógeno, alcoxi que tiene 1 a 10 carbonos, alcoxi de 1 a 10 carbonos sustituido con halógeno, alquiltio que tiene 1 a 10 carbonos, alquiltio de 1 a 10 carbonos sustituido con halógeno, alcoxi carbonilo que tiene 1 a 10 carbonos, alcoxi carbonilo que tiene 1 a 10 carbonos sustituido con halógeno, F, Cl, Br, I, NO2, CN, OCOalquilo, NH2, alquilamino y dialquilamino, en donde en dichos grupos OCOalquilo, alquilamino y dialquilamino cada uno de dichos grupos alquilo tiene 1 a 10 carbonos, carbamoílo, carbamoílo sustituido en N, alquilcarbonilo que tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alcoxi en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, grupos (alcoxicarbonil)alquilo en donde cada uno de dichos grupos alcoxi o alquilo tiene 1 a 10 carbonos, (carbamoil)alcoxi que tiene 1 a 10 carbonos, (N-alquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, (N, N-dialquilcarbamoil)alcoxi que tiene 1 a 10 carbonos, poli((carbamoil sustituido en N o no sustituido)alcoxi) que tiene 1 a 10 carbonos, (carbamoil sustituido en N o no sustituido)alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alquilo que tiene 1 a 10 carbonos, [N-(heteroaril)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(heteroaril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, [N-(aril sustituido)carbamoil]alcoxi que tiene 1 a 10 carbonos, grupo poli(alcoxi) en donde cada uno de dichos grupos alcoxi tiene 1 a 10 carbonos, polialcoxi cíclico, grupo guanidinilo, grupo ureido, grupo poli(dialquilamino - alcoxi), [N - (carbamoilalquil)carbamoil]alcoxi, [N - (carbamoilalquil)carbamoil]alquilo, [N - [[N - (heteroaril)carbamoil]alquil]carbamoil]alcoxi, [N - [[N - (heteroaril sustituido)carbamoil]alquil]carbamoil]alcoxi, [(tri - alquil)amonio]alcoxi, (sulfonato)alquilo, (sulfonato)alcoxi, N - [sulfonato)alquil]amido, maleimido (sustituido), succinimido (sustituido); y R21 es (aril)alquilo, (heteroaril)alquilo, fenilo, naftilo o heteroarilo que tiene 1 a 3 heteroátomos seleccionados independientemente entre N, O y S, estando dichos grupos fenilo, naftilo o heteroarilo, sustituidos o no sustituidos con 1 a 5 grupos R17, o a una sal farmacéuticamente aceptable de dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/131,481 US6093734A (en) | 1998-08-10 | 1998-08-10 | Prodrugs of proton pump inhibitors |
| US36438199A | 1999-07-29 | 1999-07-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2192394T3 true ES2192394T3 (es) | 2003-10-01 |
Family
ID=26829517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99942057T Expired - Lifetime ES2192394T3 (es) | 1998-08-10 | 1999-08-09 | Profarmacos de inhibidores de la bomba de protones. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6559167B1 (es) |
| EP (1) | EP1105387B1 (es) |
| JP (1) | JP4346243B2 (es) |
| KR (1) | KR100472126B1 (es) |
| CN (1) | CN100396675C (es) |
| AT (1) | ATE231857T1 (es) |
| AU (1) | AU752292B2 (es) |
| BG (1) | BG64870B1 (es) |
| BR (1) | BR9912937A (es) |
| CA (1) | CA2338311C (es) |
| DE (1) | DE69905171T2 (es) |
| DK (1) | DK1105387T3 (es) |
| ES (1) | ES2192394T3 (es) |
| FI (1) | FI20010248A7 (es) |
| HR (1) | HRP20010106A2 (es) |
| HU (1) | HUP0103464A3 (es) |
| ID (1) | ID28273A (es) |
| IL (2) | IL141083A0 (es) |
| IS (1) | IS5826A (es) |
| MX (1) | MXPA01001464A (es) |
| NO (1) | NO322490B1 (es) |
| NZ (1) | NZ510180A (es) |
| PL (1) | PL346000A1 (es) |
| TR (1) | TR200100431T2 (es) |
| UA (1) | UA67788C2 (es) |
| WO (1) | WO2000009498A1 (es) |
| YU (1) | YU10101A (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003043614A2 (en) * | 2001-11-19 | 2003-05-30 | Altana Pharma Ag | Reversible proton pump inhibitors for the treatment of airway disorders |
| KR100788778B1 (ko) | 2002-07-19 | 2007-12-27 | 윈스턴 파마슈티컬즈, 엘엘씨 | 벤즈이미다졸 유도체 및 이들의 프로톤 펌프 억제제의프로드럭으로서의 이용 |
| JP2006188432A (ja) * | 2003-02-25 | 2006-07-20 | Zeria Pharmaceut Co Ltd | 四環系スルフェンアミド化合物 |
| JP2007521314A (ja) | 2003-07-15 | 2007-08-02 | アラーガン、インコーポレイテッド | プロトンポンプ阻害薬の異性体純粋なプロドラッグを製造するための方法 |
| CA2537182A1 (en) * | 2003-08-29 | 2005-03-10 | Dynogen Pharmaceuticals, Inc. | Compositions useful for treating gastrointestinal motility disorders |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| WO2005039640A1 (en) * | 2003-10-03 | 2005-05-06 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| EP1715854A2 (en) * | 2004-02-18 | 2006-11-02 | Allergan, Inc. | Prodrugs for the intravenous administration of proton pump inhibitors |
| WO2005082337A2 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Compositions comprising prodrugs of proton pump inhibitors |
| CA2561700A1 (en) * | 2004-04-16 | 2005-12-15 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| EP1740571B1 (en) * | 2004-04-28 | 2009-07-29 | Hetero Drugs Limited | A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers |
| US7365206B2 (en) * | 2004-05-28 | 2008-04-29 | Hetero Drugs Limited | Stereoselective synthesis of benzimidazole sulfoxides |
| BRPI0512239A (pt) * | 2004-06-17 | 2008-02-19 | Wyeth Corp | processos para preparação de antagonistas de receptores de hormÈnios liberadores de gonatropina |
| EP1758895A1 (en) * | 2004-06-17 | 2007-03-07 | Wyeth a Corporation of the State of Delaware | Gonadotropin releasing hormone receptor antagonists |
| EP1805142A4 (en) * | 2004-09-23 | 2009-06-10 | Reddy Us Therapeutics Inc | PYRIDINE-BASED COMPOUNDS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME |
| CA2587853A1 (en) * | 2004-11-23 | 2006-06-01 | Wyeth | Gonadotropin releasing hormone receptor antagonists |
| US7582634B2 (en) * | 2005-02-18 | 2009-09-01 | Wyeth | 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7534796B2 (en) * | 2005-02-18 | 2009-05-19 | Wyeth | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor |
| US7538113B2 (en) * | 2005-02-18 | 2009-05-26 | Wyeth | 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor |
| US20060189619A1 (en) * | 2005-02-24 | 2006-08-24 | Wyeth | 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds |
| US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
| US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
| US7531542B2 (en) | 2005-05-18 | 2009-05-12 | Wyeth | Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor |
| US7582636B2 (en) * | 2005-05-26 | 2009-09-01 | Wyeth | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor |
| JPWO2006134877A1 (ja) * | 2005-06-13 | 2009-01-08 | 武田薬品工業株式会社 | 注射剤 |
| WO2007073301A1 (en) * | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Benzoimidazole derivatives as prodrugs of proton pump inhibitors |
| WO2008036211A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety |
| WO2008036201A1 (en) * | 2006-09-19 | 2008-03-27 | Alevium Pharmaceuticals, Inc. | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
| US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| CN101497622B (zh) * | 2008-01-30 | 2011-04-27 | 山东轩竹医药科技有限公司 | 吡啶甲基亚磺酰基咪唑并吡啶衍生物 |
| JP2011512416A (ja) | 2008-02-20 | 2011-04-21 | ザ・キュレイターズ・オブ・ザ・ユニバーシティー・オブ・ミズーリ | オメプラゾール及びランソプラゾールの組合せと緩衝剤を含んでなる組成物とそれを使用する方法 |
| UA100192C2 (en) * | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
| JP6292736B2 (ja) * | 2012-11-19 | 2018-03-14 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | ピロールスルホンアミド誘導体、その製造法およびその医療用途 |
| JP6343600B2 (ja) | 2013-02-28 | 2018-06-13 | 武田薬品工業株式会社 | スルホニルクロライド化合物の製造法 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| CN115667934A (zh) | 2020-05-20 | 2023-01-31 | 豪夫迈·罗氏有限公司 | 质谱用试剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| IL76839A (en) * | 1984-10-31 | 1988-08-31 | Byk Gulden Lomberg Chem Fab | Picoline derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
| SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
| WO1991019712A1 (en) * | 1990-06-20 | 1991-12-26 | Aktiebolaget Astra | Dialkoxy-pyridinyl-benzimidazole derivatives, process for their preparation and their pharmaceutical use |
| SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| WO1995029897A1 (en) * | 1994-04-29 | 1995-11-09 | G.D. Searle & Co. | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
| SE9602442D0 (sv) | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
-
1999
- 1999-08-09 ES ES99942057T patent/ES2192394T3/es not_active Expired - Lifetime
- 1999-08-09 HR HR20010106A patent/HRP20010106A2/hr not_active Application Discontinuation
- 1999-08-09 TR TR2001/00431T patent/TR200100431T2/xx unknown
- 1999-08-09 KR KR10-2001-7001705A patent/KR100472126B1/ko not_active Expired - Fee Related
- 1999-08-09 BR BR9912937-0A patent/BR9912937A/pt not_active Application Discontinuation
- 1999-08-09 AT AT99942057T patent/ATE231857T1/de not_active IP Right Cessation
- 1999-08-09 AU AU55518/99A patent/AU752292B2/en not_active Expired
- 1999-08-09 DE DE69905171T patent/DE69905171T2/de not_active Expired - Lifetime
- 1999-08-09 MX MXPA01001464A patent/MXPA01001464A/es not_active IP Right Cessation
- 1999-08-09 CA CA002338311A patent/CA2338311C/en not_active Expired - Lifetime
- 1999-08-09 EP EP99942057A patent/EP1105387B1/en not_active Expired - Lifetime
- 1999-08-09 HU HU0103464A patent/HUP0103464A3/hu unknown
- 1999-08-09 IL IL14108399A patent/IL141083A0/xx active IP Right Grant
- 1999-08-09 CN CNB998095125A patent/CN100396675C/zh not_active Expired - Fee Related
- 1999-08-09 NZ NZ510180A patent/NZ510180A/xx not_active IP Right Cessation
- 1999-08-09 PL PL99346000A patent/PL346000A1/xx not_active IP Right Cessation
- 1999-08-09 DK DK99942057T patent/DK1105387T3/da active
- 1999-08-09 ID IDW20010545A patent/ID28273A/id unknown
- 1999-08-09 JP JP2000564950A patent/JP4346243B2/ja not_active Expired - Fee Related
- 1999-08-09 YU YU10101A patent/YU10101A/sh unknown
- 1999-08-09 WO PCT/US1999/018048 patent/WO2000009498A1/en not_active Ceased
- 1999-09-08 UA UA2001020908A patent/UA67788C2/uk unknown
-
2001
- 2001-01-24 IL IL141083A patent/IL141083A/en not_active IP Right Cessation
- 2001-01-26 BG BG105191A patent/BG64870B1/bg unknown
- 2001-01-26 IS IS5826A patent/IS5826A/is unknown
- 2001-02-09 FI FI20010248A patent/FI20010248A7/fi unknown
- 2001-02-09 NO NO20010693A patent/NO322490B1/no not_active IP Right Cessation
- 2001-02-14 US US09/783,807 patent/US6559167B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI831604L (fi) | Pyridinderivat, deras framstaellning och anvaendning | |
| ES2190264T3 (es) | N-(2-aril-propionil)sulfonamidas y preparaciones farmaceuticas que las contienen. | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| ATE316961T1 (de) | Heterozyclische derivate für die behandlung von herzversagen und andere erkrankungen | |
| PT93111A (pt) | Processo para a preparacao de compostos heterociclicos contendo pelo menos dois atomos de azoto no anel | |
| RU2004119406A (ru) | 5-сульфанил-4н-1,2,4-триазольные производные и их применение в качестве лекарственного препарата | |
| DK0624584T3 (da) | Piperazinderivater, der er nyttige som calmodulininhibitorer | |
| AR057244A1 (es) | Compuestos agonistas,antagonistas o agonistas inversos de receptores cb2,composiciones farmaceuticas que los contienen, metodos de preparacion y usos para tratar enfermedades inflamatorias y/o autoinmunes. | |
| EA200001172A1 (ru) | Терапевтические диарильные производные | |
| HUP0402026A2 (hu) | 5,6-Diaril-pirazin-2-amid-származékok mint CB1 antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| BE1002226A5 (fr) | Derives de 4h-benzopyranne-1 one-4 et leurs sels, leurs procedes de fabrication et compositions pharmaceutiques les comprenant en tant qu'ingredients actifs. | |
| ES2075849T3 (es) | Derivados heterociclicos. | |
| BG100511A (en) | Indole derivatives as nmda antagoniosts | |
| RU2002129100A (ru) | Гетероциклические производные и лекарственные средства | |
| RU97103983A (ru) | Лекарственные композиции и производные триазина | |
| RU2004119963A (ru) | Ингибиторы вич интегразы | |
| RU2003130752A (ru) | Противозудные средства | |
| CO4810374A1 (es) | Nueva utilizacion de compuestos para actividad anti- pruritica | |
| DK270289D0 (da) | Oligopeptider med cycliske, prolin-analoge aminosyrer og farmaceutisk acceptable salte deraf samt deres anvendelse | |
| GB1369401A (en) | Process for the manufacture of 2-amino-1,4-dihydropyridines and their use as coronary agents | |
| DE68925933D1 (de) | Arylalkylamine und -amide mit krampflösender und nervenschützender Wirkung | |
| KR910000133A (ko) | 아민 | |
| RU2002118708A (ru) | Гетероциклические производные и лекарственные средства | |
| AR015140A1 (es) | N-(3,4-dihidro-2h-piran-4-il)sulfonamidas, procedimiento para su preparacion, su utilizacion para la preparacion de un medicamento, un preparadofarmaceutico y medicamento | |
| RU2003123119A (ru) | Модуляторы натриевых каналов, являющиеся производными 2-пиперидилимидазолов |